Simultaneous treatment of Samter triad and prurigo nodularis with dupilumab

Bloomstein, Joshua; Hawkes, Jason E.

doi:10.1016/j.jdcr.2021.10.005

Cited by 3 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Beyond dermatology, dupilumab is also effective and approved for moderate-to-severe asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP) [ 6 ] and eosinophilic esophagitis. In addition, efficacy of dupilumab in prurigo nodularis (PN) and other forms of chronic prurigo was previously shown in several reports [ 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 ]. The phase 3 clinical trials LIBERTY-PN PRIME and PRIME2 showed significantly reduced itch, amelioration of skin lesions, sleep, pain and quality of life compared to placebo treatment in a total of 153 treated patients (NCT04202679, NCT04183335).…”

Section: Introductionmentioning

confidence: 99%

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was approved by the U.S. Food and Drug Administration for prurigo nodularis (PN). Given its relatively good safety profile, effective off-label use of dupilumab has been reported for a multitude of dermatologic diseases and several clinical trials for dermatologic skin conditions are currently ongoing. We conducted a systematic review of applications of dupilumab in dermatology other than AD and PN by searching the databases PubMed/Medline, Scopus, Web of Science and Cochrane Library as well as the clinical trial registry ClinicalTrials.gov. We found several reports for effective treatment of bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome and a variety of other chronic inflammatory skin diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…It has also shown tremendous promise as a treatment for non-atopic and pruritus-related conditions (eg, keloids and bullous pemphigoid). 6 The role of dupilumab in the management of LP and LP-associated pruritus has not been studied in clinical trials. Here, we describe an elderly patient with widespread cutaneous LP and severe, generalized pruritus who experienced rapid resolution of her skin lesions and itching following treatment with dupilumab.…”

Section: Introductionmentioning

confidence: 99%

Rapid resolution of widespread cutaneous lichen planus and generalized pruritus in an elderly patient following treatment with dupilumab

Kazemi¹,

Murphrey²,

Hawkes³

2022

JAAD Case Reports

Self Cite

View full text Add to dashboard Cite

Dupilumab for the treatment of prurigo nodularis: A systematic review

Cao

Jiang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

BackgroundConventional treatment techniques have limited efficacy and more side effects in the treatment of prurigo nodularis. The better alternative treatment option for better outcomes of the disease is dupilumab.ObjectiveThe objective of this study was to systematically review dupilumab-related treatment outcomes in prurigo nodularis.MethodsSeveral databases like Embase, PubMed, Web of Science, and Cochrane library were searched for data acquisition on October 8, 2022. Based on Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, 24 publications were included in this study.ResultsAfter 4,12,16 and more than 16 weeks of dupilumab treatment, 8.3% (n=5/60), 34.4% (n=11/32), 3.6% (n=2/56), and 45.3% (n=29/64) of patients had complete remission, respectively. In addition, 85.0% (n=51/60), 59.4% (n=19/32), 83.9% (n=47/56), and 43.8% (n=28/64) had partial remission, respectively. Moreover, 6.7% (n=4/60), 6.3% (n=2/32), 12.5% (n=7/56), and 10.9% (n=7/64) showed no remission, respectively, and significant reduction of numeric rating scale itch intensity (from 9.0 to 4.9, 2.1, 2.8, 0.9) was attained. There were no serious adverse events observed during treatment, but the most common event observed was conjunctivitis (12.6%, n=15/119).ConclusionsDupilumab has definite effectiveness and safety in prurigo nodularis treatment.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO, identifier (CRD42022365802).

show abstract

Simultaneous treatment of Samter triad and prurigo nodularis with dupilumab

Cited by 3 publications

References 9 publications

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Rapid resolution of widespread cutaneous lichen planus and generalized pruritus in an elderly patient following treatment with dupilumab

Dupilumab for the treatment of prurigo nodularis: A systematic review

Contact Info

Product

Resources

About